<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23033" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Human Papilloma Virus Vaccine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Soca Gallego</surname>
            <given-names>Lucia</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dominguez</surname>
            <given-names>Alvio</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lucia Soca Gallego declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alvio Dominguez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23033.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">The 9-valent human papillomavirus (HPV) vaccine (9vHPV) is a second-generation, noninfectious, recombinant vaccine available in the United States and indicated for the management and prevention of infections, diseases, or cancers caused by both low-risk and high-risk HPV types, including 6, 11, 16, 18, 31, 33, 45, 52, and 58.&#x000a0;HPVs are the leading sexually transmitted viruses responsible for precancerous and cancerous lesions. The 9vHPV has been licensed by the US Food and Drug Administration (FDA) since 2014 and is classified as a preventive immunization.</p>
        <p>The exact mechanism of action of 9vHPV&#x000a0;remains unclear, as&#x000a0;HPV only affects humans, which poses challenges for research. However, researchers hypothesize that the vaccine operates by triggering the humoral response. This activity comprehensively examines the indications, actions, and contraindications of the 9vHPV vaccine as a crucial tool in managing and preventing HPV infection and associated diseases. Furthermore, this activity underscores the mechanism of action, adverse event profile, and other essential considerations regarding administering the 9vHPV vaccine, which is crucial for clinicians in delivering HPV immunization to patients effectively.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify individuals eligible for the human papillomavirus vaccine (9vHPV) based on current guidelines, considering age, gender, and other relevant factors.</p></list-item><list-item><p>Differentiate between the various human papillomavirus vaccines (HPV) available, including the bivalent, quadrivalent, and 9-valent formulations, based on their indications, dosing schedules, and target HPV types.</p></list-item><list-item><p>Implement evidence-based protocols for administering the human papillomavirus vaccine, ensuring adherence to recommended dosing schedules and administration routes.</p></list-item><list-item><p>Collaborate with other healthcare providers, such as pharmacists, nurses, and public health officials, to promote human papillomavirus&#x000a0;vaccination initiatives and ensure comprehensive vaccination coverage within the community.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23033&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23033">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23033.s2" sec-type="Indications">
        <title>Indications</title>
        <p>The 9-valent human papillomavirus (HPV) vaccine (9vHPV) is a second-generation, noninfectious, recombinant vaccine available in the United States and indicated for the management and prevention of infections, diseases, or cancers caused by both low-risk and high-risk HPV types, including 6, 11, 16, 18, 31, 33, 45, 52, and 58.&#x000a0;HPVs are the leading sexually transmitted viruses responsible for precancerous and cancerous lesions. The 9vHPV has been licensed by the US Food and Drug Administration (FDA) since 2014 and is classified as a preventive immunization.&#x000a0;The exact mechanism of action of 9vHPV&#x000a0;remains unclear, as&#x000a0;HPV only affects humans, which&#x000a0;poses challenges for research.&#x000a0;However, researchers hypothesize that the vaccine operates by triggering the humoral response.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The 3 different FDA-approved vaccines designed to protect against infection from different numbers of HPV types are mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>2vHPV (bivalent vaccine): Protects against HPV types 16 and 18. Although this vaccine is unavailable in the United States, it is still used in other countries.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>4vHPV (quadrivalent vaccine): Protects against HPV types 6, 11, 16, and 18.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>9vHPV (9-valent vaccine): Protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58.&#x000a0;This is the only HPV vaccine available in the United States that confers protection against these specific HPV types.</p>
          </list-item>
        </list>
        <p>The 9vHPV vaccine is routinely recommended for males and females aged 9 to 45 to prevent various diseases and dysplastic lesions caused by HPV,<xref ref-type="bibr" rid="article-23033.r1">[1]</xref>&#x000a0;which include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Anal, oropharyngeal, cervical, vulvar, vaginal, and other head-and-neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Condyloma acuminata (genital warts) caused by HPV types 6 and 11.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cervical adenocarcinoma in situ, anal, cervical, vulvar, and vaginal intraepithelial neoplasias caused by HPV types 16, 18, 31, 33, 45, 52, and 58.</p>
          </list-item>
        </list>
        <p>Routine vaccination with&#x000a0;9vHPV is&#x000a0;recommended for several patient populations,<xref ref-type="bibr" rid="article-23033.r2">[2]</xref>&#x000a0;which include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Males and females&#x000a0;aged 9 through 45 who have not previously received a vaccination or who did not complete the currently recommended 3-dose regimen.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Men who have sex with men (MSM)&#x000a0;aged 26 and&#x000a0;older.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with the immunocompromised state who have no prior vaccination or who did not complete the 3-dose regimen.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Victims of sexual abuse or assault.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Transgender individuals/.</p>
          </list-item>
        </list>
        <p>Vaccination with 9vHPV does not replace the need for regular screening for cervical, vulvar, vaginal, anal, oropharyngeal, and other head and neck cancers.</p>
      </sec>
      <sec id="article-23033.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The exact mechanism of action of 9vHPV is unknown. Nevertheless,&#x000a0;researchers believe that the vaccine works by activating the humoral response. 9vHPV is a noninfectious recombinant vaccine containing purified virus-like particles (VLPs)&#x000a0;obtained from the major capsid (L1) protein of HPV serotypes 6, 11, 16, 18, 31, 33, 45, 52, and 58. The L1 proteins are separated using recombinant <italic toggle="yes">Saccharomyces cerevisiae</italic> and self-assembled into VLPs. Each 0.5 mL dose of the vaccine contains aluminum, sodium chloride, L-histidine, polysorbate, sodium borate, yeast protein less than 7 mcg, and water. The product does not contain preservatives or antibiotics.<xref ref-type="bibr" rid="article-23033.r3">[3]</xref><xref ref-type="bibr" rid="article-23033.r4">[4]</xref></p>
        <p>A 2016 immunogenicity study reports that the inactive HPV L1 VLPs in the vaccine produce neutralizing antibodies against HPV types, eliciting a strong humoral immune response to protect against the dysplastic lesions caused by HPV. The same study reported that antibody titers for 9vHPV are 10- to 100-fold more significant than those produced by natural infection. Thus, the vaccine's efficacy&#x000a0;is mediated via humoral response mechanisms.<xref ref-type="bibr" rid="article-23033.r5">[5]</xref></p>
      </sec>
      <sec id="article-23033.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>9vHPV administration is an intramuscular (IM) injection in the deltoid region or anterolateral thigh area. A single dose for adults and pediatric patients consists of a 0.5-mL suspension. 9vHPV is administered in a 2- or 3-dose schedule depending on the patient's age at initial vaccination.<xref ref-type="bibr" rid="article-23033.r6">[6]</xref></p>
        <p>
<bold>Dosages</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Two-dose schedule&#x000a0;for patients aged 9 through 14 at initial vaccination:
<list list-type="bullet"><list-item><p>0, 6 to 12 months: A minimum of&#x000a0;5 months between doses.</p></list-item><list-item><p>0, 2, 6 months: If administration of the second suspension occurs before the 5-month mark, then a third suspension should be administered&#x000a0;4 months after the second dose, at the latest.<xref ref-type="bibr" rid="article-23033.r6">[6]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Three-dose schedule for patients aged 15 through 45 at initial vaccination according to manufacturer's labeling (may not reflect current clinical practice):
<list list-type="bullet"><list-item><p>0, 2, 6 months<xref ref-type="bibr" rid="article-23033.r6">[6]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>The series can continue as previously scheduled and does not need to be restarted if the schedule is interrupted.<xref ref-type="bibr" rid="article-23033.r2">[2]</xref>&#x000a0;Lastly, 9vHPV can&#x000a0;be administered simultaneously with other routine vaccinations such as the meningococcal (groups A, C, Y, and W-135), polysaccharide diphtheria toxoid conjugate vaccine, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap).&#x000a0;Coadministration of 9vHPV with either of these vaccinations is well tolerated and does not interfere with&#x000a0;the effect; however, the recommendation is to administer in different body sites.<xref ref-type="bibr" rid="article-23033.r7">[7]</xref></p>
        <p>Current vaccination recommendations are based on the guidelines provided by the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP).<xref ref-type="bibr" rid="article-23033.r8">[8]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Routine vaccination is recommended for all individuals aged 11 to 12, with the option to begin vaccination as early as age 9. The&#x000a0;American Academy of Pediatrics (AAP) suggests&#x000a0;initiating&#x000a0;the HPV vaccine series for patients aged 9 through 12.&#x000a0;According to the AAP guidelines, parents or adolescents who avoid&#x000a0;3 or more concomitant vaccines at age 11 or 12 may&#x000a0;prefer to initiate the vaccine at age 9 or 10. The American Academy of Pediatrics (AAP) policy aims to promote the introduction of the HPV vaccine at an earlier age to achieve higher vaccine initiation and completion rates.<xref ref-type="bibr" rid="article-23033.r9">[9]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>ACIP also recommends vaccination for everyone through age 26 if not adequately vaccinated when younger.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>ACIP recommended shared clinical decision-making for patients aged 27 to 45.</p>
          </list-item>
        </list>
        <p>
<bold>Patients aged 9 to 15:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Two doses of the HPV vaccine are recommended for most patients.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The second dose of the HPV vaccine is administered 6 to 12 months after the first dose.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Adolescents who have received&#x000a0;2 doses less than&#x000a0;5 months apart require a third dose of the HPV vaccine.</p>
          </list-item>
        </list>
        <p>
<bold>Patients aged&#x000a0;15 to 26:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Three doses of the HPV vaccine are recommended for teens and young adults who start the series at ages 15 through 26.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The recommended three-dose schedule is 0, 1&#x000a0;to 2, and 6 months.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Three doses are recommended for a patient with immunocompromised conditions (eg, HIV infection, immunosuppressive therapy)</p>
          </list-item>
        </list>
        <p>
<bold>Patients aged&#x000a0;27 to 45:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>ACIP (2019) recommended shared clinical decision-making for patients aged 27 to 45, as most adults in this age group have minimal benefits from vaccination.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Individuals who are not already immunized to HPV (eg, a previously unvaccinated person who has never had sex) and the person at risk for acquiring a newer HPV infection soon (eg, who plans to have sex with a new partner) might get benefit from vaccination.<xref ref-type="bibr" rid="article-23033.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>HPV vaccines are not licensed in adults aged 45 and older.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment: </bold>The manufacturer's product labeling provides no information regarding dose adjustment in patients with hepatic impairment.</p>
        <p><bold>Renal impairment: </bold>The manufacturer's product labeling provides no information regarding dose adjustment in patients with&#x000a0;renal impairment.</p>
        <p><bold><bold>Pregnancy considerations: </bold></bold>According to the CDC and the American College of Obstetricians and Gynecologists&#x000a0;(ACOG), the&#x000a0;HPV vaccine is not recommended during pregnancy. However, if the vaccine is accidentally administered to a pregnant woman, the patient should be informed that available safety data are reassuring. In addition, if a vaccine series is initiated and a patient becomes pregnant, the clinician should postpone the vaccine series until&#x000a0;the pregnancy is completed.<xref ref-type="bibr" rid="article-23033.r11">[11]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>According to the CDC, vaccines given to a nursing mother do not impact breastfeeding safety for mothers or infants. For instance, a slightly higher percentage of breastfed infants with the active quadrivalent&#x000a0;HPV vaccine had pneumonia 30 days after maternal vaccination. Still, these effects were not attributable to the vaccine. Maternal vaccination is not a contraindication to breastfeeding; clinicians may administer the HPV to breastfeeding patients.<xref ref-type="bibr" rid="article-23033.r12">[12]</xref>&#x000a0;According to ACOG 2020 guidelines, the&#x000a0;HPV vaccine should be administered to breastfeeding women aged 26 and younger who have not been previously vaccinated.<xref ref-type="bibr" rid="article-23033.r11">[11]</xref></p>
      </sec>
      <sec id="article-23033.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse effects recorded&#x000a0;with 9vHPV are injection-site events, systemic events, and syncope.<xref ref-type="bibr" rid="article-23033.r13">[13]</xref><xref ref-type="bibr" rid="article-23033.r14">[14]</xref>&#x000a0;Injection-site events were recorded within&#x000a0;5 days after vaccination, including pain, swelling, erythema, and tenderness.<xref ref-type="bibr" rid="article-23033.r14">[14]</xref><xref ref-type="bibr" rid="article-23033.r15">[15]</xref>&#x000a0;Systemic events were recorded within&#x000a0;15 days&#x000a0;following vaccination, including headaches, pyrexia, fatigue, and nausea.<xref ref-type="bibr" rid="article-23033.r15">[15]</xref>&#x000a0;Syncope after administration of 9vHPV&#x000a0;is reported, occurring post-administration of the vaccine and posing a significant risk of severe secondary injury to patients.</p>
        <p>A 2016 study concluded that incidences of adverse effects were comparable&#x000a0;in all age groups.<xref ref-type="bibr" rid="article-23033.r6">[6]</xref>&#x000a0;This study also concluded that the safety profile of 9vHPV is comparable to its quadrivalent counterpart, 4vHPV. Injection site effects&#x000a0;are common with&#x000a0;9vHPV, given more HPV virus-like antigens and aluminum hydroxyphosphate sulfate adjuvants, which help potentiate the immunological response.<xref ref-type="bibr" rid="article-23033.r16">[16]</xref></p>
        <p>Postmarketing surveillance of the&#x000a0;HPV&#x000a0;vaccine has identified&#x000a0;multiple adverse events following immunization, such as abdominal pain, syncope, dizziness,&#x000a0;loss of consciousness, alopecia, amenorrhea, anemia, dyskinesia, migraine,&#x000a0;pallor, and seizures.<xref ref-type="bibr" rid="article-23033.r17">[17]</xref></p>
        <p>According to a comprehensive surveillance study conducted over&#x000a0;5 years involving the administration of more than 1.8 million doses of the 9vHPV vaccine to individuals aged 9&#x000a0;to 26, no statistically significant increases in the risk of Guillain-Barr&#x000e9; syndrome, chronic inflammatory demyelinating polyneuropathy, or stroke were observed following vaccination with the 9vHPV vaccine. These longer-term findings&#x000a0;endorse the safety of the 9vHPV vaccine.<xref ref-type="bibr" rid="article-23033.r18">[18]</xref></p>
        <p>
<bold>Drug-Vaccine Interactions</bold>
</p>
        <p>Immunosuppressive therapies, such as irradiation, alkylating agents, antimetabolites, cytotoxic medications, and corticosteroids, attenuate immune responses to the HPV vaccine.</p>
      </sec>
      <sec id="article-23033.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Vaccine-related anaphylactic reactions are uncommon; however, anaphylaxis to a known vaccine ingredient is an absolute contraindication to immunization.<xref ref-type="bibr" rid="article-23033.r13">[13]</xref>&#x000a0;As a result, 9vHPV is contraindicated in individuals with a history of hypersensitivity reactions to yeast since 9vHPV is a recombinant vaccine expressed in&#x000a0;<italic toggle="yes">S cerevisiae&#x000a0;</italic>(brewer&#x02019;s yeast).<xref ref-type="bibr" rid="article-23033.r2">[2]</xref></p>
        <p>Contraindications include persons with previous hypersensitivity reactions to a dose of 9vHPV or&#x000a0;4vHPV (quadrivalent vaccine).<xref ref-type="bibr" rid="article-23033.r2">[2]</xref>&#x000a0;According to the CDC, moderate or severe acute illness is a precaution to vaccination, and clinicians should postpone vaccination until symptoms of the critical illness improve.</p>
        <p>The safety of 9vHPV&#x000a0;has not been studied in pregnant human subjects; thus, 9vHPV is not currently recommended in pregnancy. A 2018 animal study assessed the general, reproductive, and developmental toxicity of 9vHPV in Sprague-Dawley rats. The study followed a 3-month repeat-dose toxicity study on rats, reporting no effects on the reproductive ability of rats, no effects on offspring development, no vaccine-related fetal abnormalities, and no effect on male rat fertility.<xref ref-type="bibr" rid="article-23033.r19">[19]</xref>&#x000a0;</p>
        <p>These results add to the available data that 9vHPV does not increase the risk of adverse pregnancy outcomes in rats; however, more studies need to evaluate the safety profile in pregnant human subjects. Currently, standard protocol dictates that if a&#x000a0;patient is pregnant, the vaccination series should be halted and resumed after pregnancy.<xref ref-type="bibr" rid="article-23033.r20">[20]</xref></p>
      </sec>
      <sec id="article-23033.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Syncope, occasionally accompanied by tonic-clonic movements and other seizure-like activity,&#x000a0;is documented as a potential adverse effect following HPV vaccination. Patients should receive monitoring for syncopal events to prevent severe secondary injury to the patient.</p>
        <p>Clinicians&#x000a0;should monitor patients for presyncope signs and symptoms for 15 minutes when administering 9vHPV. Additionally, standard operating procedures should be in place to avoid severe secondary injuries resulting from the patient's collapse; these include keeping the patient in a Trendelenburg or supine position to maintain adequate cerebral perfusion. Patients should&#x000a0;be monitored for acute onset of signs and symptoms of anaphylactic reactions such as hypotension, tachycardia, urticaria, and respiratory compromise.<xref ref-type="bibr" rid="article-23033.r21">[21]</xref></p>
      </sec>
      <sec id="article-23033.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>9vHPV is a generally well-tolerated vaccine with a&#x000a0;robust safety profile. The most common adverse effects are minor issues such as injection-site pain, swelling, erythema, and tenderness.<xref ref-type="bibr" rid="article-23033.r14">[14]</xref>&#x000a0;Minor systemic effects have been reported, such as headaches, pyrexia, fatigue, and nausea.<xref ref-type="bibr" rid="article-23033.r15">[15]</xref>&#x000a0;</p>
        <p>Toxic effects are attributable to anaphylaxis and hypersensitivity reactions. In the case of an anaphylactic reaction, clinicians should immediately administer 1.0 mg/mL of epinephrine via the IM route in the anterolateral vastus lateralis muscle. Administration of IM epinephrine should be repeated every 5 to 15 minutes until the desired response is achieved.<xref ref-type="bibr" rid="article-23033.r22">[22]</xref></p>
      </sec>
      <sec id="article-23033.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>According to the 2019 ACIP report,&#x000a0;HPV is responsible for an estimated 33,700 cancer cases annually in the United States. This includes 12,900 cases of oropharyngeal cancers among both men and women, 10,800 cases of cervical cancer among women, and 6,000 cases of anal cancer among both men and women. Although vaginal, vulvar, and penile cancers are relatively less frequent, they are also associated with HPV infection.<xref ref-type="bibr" rid="article-23033.r8">[8]</xref>&#x000a0;</p>
        <p>Clinicians should recognize that&#x000a0;the burden of HPV-related mortality is significantly greater than the combined mortality caused by tetanus, diphtheria, pertussis, and meningococcal disease.<xref ref-type="bibr" rid="article-23033.r9">[9]</xref>&#x000a0;To support widespread vaccination efforts and increase the global prevention of diseases and dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, clinicians must increase patient awareness during wellness visits&#x000a0;regarding the importance of HPV vaccination.&#x000a0;Interprofessional team members should also educate their patients on the different cancers and avoidable precancerous lesions when immunized with 9vHPV. Patients must be urged to complete the recommended three-dose sequence of 9vHPV.&#x000a0;</p>
        <p>Clinicians can increase vaccine&#x000a0;compliance&#x000a0;by scheduling follow-up visits in person. Further, clinics, pharmacies, and hospitals should implement standard operating procedures to prevent severe injury, such as safe vaccine administration spaces.&#x000a0;</p>
        <p>Interventions that include healthcare education, tailored systems changes, feedback, and early initiation of the HPV vaccine may improve patient adherence and completion of vaccination schedules.<xref ref-type="bibr" rid="article-23033.r23">[23]</xref><bold>&#x000a0;</bold>Moreover, healthcare professionals should be aware of and attentive to the acute onset of symptoms of an anaphylactic reaction.</p>
        <p>All healthcare team members should receive training in the administration of epinephrine auto-injectors. Clinicians should&#x000a0;prescribe the HPV vaccine according to the latest ACIP and CDC recommendations. Nurses should administer and monitor for adverse reactions. Pharmacists should report adverse events following immunization by the Vaccine Adverse Event Reporting System (VAERS), which would enhance patient safety.<xref ref-type="bibr" rid="article-23033.r24">[24]</xref>&#x000a0;Interprofessional collaboration between clinicians and pharmacists facilitates improved outcomes with reduced adverse reactions, along with higher vaccination rates and increased public awareness regarding the significance of the 9vHPV vaccination.</p>
      </sec>
      <sec id="article-23033.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23033&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23033">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23033/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23033">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23033.s11">
        <title>References</title>
        <ref id="article-23033.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Printz</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>FDA approves Gardasil 9 for more types of HPV.</article-title>
            <source>Cancer</source>
            <year>2015</year>
            <month>Apr</month>
            <day>15</day>
            <volume>121</volume>
            <issue>8</issue>
            <fpage>1156</fpage>
            <page-range>1156-7</page-range>
            <pub-id pub-id-type="pmid">25855331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petrosky</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bocchini</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hariri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chesson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Saraiya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>LE</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention (CDC)</collab>
            </person-group>
            <article-title>Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2015</year>
            <month>Mar</month>
            <day>27</day>
            <volume>64</volume>
            <issue>11</issue>
            <fpage>300</fpage>
            <page-range>300-4</page-range>
            <pub-id pub-id-type="pmid">25811679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harper</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>DeMars</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>HPV vaccines - A review of the first decade.</article-title>
            <source>Gynecol Oncol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>146</volume>
            <issue>1</issue>
            <fpage>196</fpage>
            <page-range>196-204</page-range>
            <pub-id pub-id-type="pmid">28442134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schiller</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Kines</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Current understanding of the mechanism of HPV infection.</article-title>
            <source>Gynecol Oncol</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>118</volume>
            <issue>1 Suppl</issue>
            <fpage>S12</fpage>
            <page-range>S12-7</page-range>
            <pub-id pub-id-type="pmid">20494219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castle</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Maza</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prophylactic HPV vaccination: past, present, and future.</article-title>
            <source>Epidemiol Infect</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>144</volume>
            <issue>3</issue>
            <fpage>449</fpage>
            <page-range>449-68</page-range>
            <pub-id pub-id-type="pmid">26429676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moreira</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Block</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Ferris</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Giuliano</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Iversen</surname>
                <given-names>OE</given-names>
              </name>
              <name>
                <surname>Joura</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Kosalaraksa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schilling</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Van Damme</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bornstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Pils</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cuzick</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garland</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kjaer</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hyatt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moeller</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ritter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baudin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luxembourg</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials.</article-title>
            <source>Pediatrics</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>138</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">27422279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schilling</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parra</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Gutierrez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Restrepo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ucros</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Herrera</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Engel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Huicho</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shew</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maansson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Caldwell</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Luxembourg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ter Meulen</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines.</article-title>
            <source>Pediatrics</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>136</volume>
            <issue>3</issue>
            <fpage>e563</fpage>
            <page-range>e563-72</page-range>
            <pub-id pub-id-type="pmid">26240207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meites</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Szilagyi</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Chesson</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2019</year>
            <month>Aug</month>
            <day>16</day>
            <volume>68</volume>
            <issue>32</issue>
            <fpage>698</fpage>
            <page-range>698-702</page-range>
            <pub-id pub-id-type="pmid">31415491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Leary</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>Why the American Academy of Pediatrics recommends initiating HPV vaccine at age 9.</article-title>
            <source>Hum Vaccin Immunother</source>
            <year>2022</year>
            <month>Nov</month>
            <day>30</day>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>2146434</fpage>
            <pub-id pub-id-type="pmid">36404635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'leary</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Maldonado</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Kimberlin</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Update From the Advisory Committee on Immunization Practices.</article-title>
            <source>J Pediatric Infect Dis Soc</source>
            <year>2019</year>
            <month>Dec</month>
            <day>27</day>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>495</fpage>
            <page-range>495-500</page-range>
            <pub-id pub-id-type="pmid">31589289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians and Gynecologists' Committee on Adolescent Health Care, American College of Obstetricians and Gynecologists' Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group</collab>
            <article-title>Human Papillomavirus Vaccination: ACOG Committee Opinion, Number 809.</article-title>
            <source>Obstet Gynecol</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>136</volume>
            <issue>2</issue>
            <fpage>e15</fpage>
            <page-range>e15-e21</page-range>
            <pub-id pub-id-type="pmid">32732766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <chapter-title>Human Papillomavirus Vaccines</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>9</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30000765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brotherton</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Burgess</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Campbell-Lloyd</surname>
                <given-names>S</given-names>
              </name>
              <collab>New South Wales Health HPV Adverse Events Panel</collab>
            </person-group>
            <article-title>Anaphylaxis following quadrivalent human papillomavirus vaccination.</article-title>
            <source>CMAJ</source>
            <year>2008</year>
            <month>Sep</month>
            <day>09</day>
            <volume>179</volume>
            <issue>6</issue>
            <fpage>525</fpage>
            <page-range>525-33</page-range>
            <pub-id pub-id-type="pmid">18762618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Signorelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Odone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ciorba</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cella</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Audisio</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Lombardi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mariani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mennini</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Pecorelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rezza</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zuccotti</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Peracino</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence.</article-title>
            <source>Epidemiol Infect</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>145</volume>
            <issue>10</issue>
            <fpage>1962</fpage>
            <page-range>1962-1982</page-range>
            <pub-id pub-id-type="pmid">28446260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yusupov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Popovsky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mahmood</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Akman</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The nonavalent vaccine: a review of high-risk HPVs and a plea to the CDC.</article-title>
            <source>Am J Stem Cells</source>
            <year>2019</year>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>52</fpage>
            <page-range>52-64</page-range>
            <pub-id pub-id-type="pmid">31976155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mold</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shardlow</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Exley</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Insight into the cellular fate and toxicity of aluminium adjuvants used in clinically approved human vaccinations.</article-title>
            <source>Sci Rep</source>
            <year>2016</year>
            <month>Aug</month>
            <day>12</day>
            <volume>6</volume>
            <fpage>31578</fpage>
            <pub-id pub-id-type="pmid">27515230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Subeesh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Beulah</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gouri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maheswari</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Postlicensure surveillance of human papillomavirus vaccine using the Vaccine Adverse Event Reporting System, 2006-2017.</article-title>
            <source>Perspect Clin Res</source>
            <year>2020</year>
            <season>Jan-Mar</season>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-30</page-range>
            <pub-id pub-id-type="pmid">32154146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sundaram</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kieke</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Hanson</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Belongia</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Weintraub</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Hechter</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Naleway</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Donahue</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Extended surveillance to assess safety of 9-valent human papillomavirus vaccine.</article-title>
            <source>Hum Vaccin Immunother</source>
            <year>2022</year>
            <month>Dec</month>
            <day>30</day>
            <volume>18</volume>
            <issue>7</issue>
            <fpage>2159215</fpage>
            <pub-id pub-id-type="pmid">36577134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wise</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Plitnick</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of a 9-valent HPV vaccine in Sprague-Dawley rats: Nonclinical studies assessing general, reproductive, and developmental toxicity.</article-title>
            <source>Vaccine</source>
            <year>2018</year>
            <month>Oct</month>
            <day>15</day>
            <volume>36</volume>
            <issue>43</issue>
            <fpage>6401</fpage>
            <page-range>6401-6407</page-range>
            <pub-id pub-id-type="pmid">30236634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markowitz</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Dunne</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Saraiya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chesson</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Gee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bocchini</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>ER</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention (CDC)</collab>
            </person-group>
            <article-title>Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2014</year>
            <month>Aug</month>
            <day>29</day>
            <volume>63</volume>
            <issue>RR-05</issue>
            <fpage>1</fpage>
            <page-range>1-30</page-range>
            <pub-id pub-id-type="pmid">25167164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r21">
          <label>21</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Clark</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Pippin</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <chapter-title>Safe and Effective Administration of Vaccines and Epinephrine Autoinjection</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">33620849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LoVerde</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Iweala</surname>
                <given-names>OI</given-names>
              </name>
              <name>
                <surname>Eginli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krishnaswamy</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis.</article-title>
            <source>Chest</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>153</volume>
            <issue>2</issue>
            <fpage>528</fpage>
            <page-range>528-543</page-range>
            <pub-id pub-id-type="pmid">28800865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perkins</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Legler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pierre-Joseph</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Eun</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Biancarelli</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Schuch</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Leschly</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fenton</surname>
                <given-names>ATHR</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Drainoni</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Hanchate</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Improving HPV Vaccination Rates: A Stepped-Wedge Randomized Trial.</article-title>
            <source>Pediatrics</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>146</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">32540986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23033.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sonawane</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Damgacioglu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Montealegre</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Cazaban</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lairson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Giuliano</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Deshmukh</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States.</article-title>
            <source>JAMA Netw Open</source>
            <year>2021</year>
            <month>Sep</month>
            <day>01</day>
            <volume>4</volume>
            <issue>9</issue>
            <fpage>e2124502</fpage>
            <pub-id pub-id-type="pmid">34533574</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
